Patient | Intervention (mode of administration) | Intervention (dose and dose frequency studied) | Intervention (duration of therapy) | Comparator | Outcome measures* | Study type |
---|---|---|---|---|---|---|
Children and adults with vitiligo | Topical or systemic Janus kinase (JAK) inhibitors | Various doses and frequencies | Within 1Â year or longer | Standard therapy | Quality of life | Observational or interventional |
 |  |  |  |  | Percentage of repigmentation |  |
 |  |  |  |  | Cosmetic acceptability of repigmentation |  |
 |  |  |  |  | Decreased spreading of the disease |  |
 |  |  |  |  | Lasting repigmentation due to treatment after a 2-year follow-up |  |
 |  |  |  |  | Tolerability or burden of treatment |  |
 |  |  |  |  | Adverse events |  |